CSI Market
Sign In | Register

Karyopharm Therapeutics Inc (KPTI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KPTI Annual Cash Flow →
This page allows investors to follow Karyopharm Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-89.42
Depreciation & amortization0.01
Amortization of Other Assets4.92
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.04
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation4.94
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Consulting Expense-
Increase Decrease In Operating Lease Right Of Use Asset0.14
Marketable Securities Gain Loss-
Embedded Derivative Gain Loss On Embedded Derivative Net-16.48
Increase Decrease In Contract With Customer Liability-
Research And Development In Process-
Interest Expense Long Term Debt6.91
Covertible Senior Notes Issued With Warrant In Exchange Of Deferred Royalty Obligation-
Notes Issued-
Stock Issued-
Increase Decrease In Operating Lease Liabilities-0.23
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable3.69
Increase (Decrease) in Accounts Payable3.66
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.51
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.78
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.09
Payments for (Proceeds from) Other Operating Activities22.77
Discontinued operations0.00
Net Cash flow from Operating Activities-47.66
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities3.20
Payments to Acquire Available-for-sale Securities, Debt-10.04
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-6.84
Financing Activities
Short-term debt Net0.00
Other borrowing transactions1.90
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.81
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net26.19
Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Payments For Common Stock Issuance Net-
Proceeds From Deferred Royalty Obligation-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents60.89
Proceeds From Deferred Royalty Obligation Net-
Proceeds From Amended Revenue Interest Agreement-
Payment Of Deferred Royalty Obligation-
Proceeds From Issuance Of Common Stock And Warrants In Private Placement Offering30.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities48.90
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-47.66
Total Cash Flow-5.59
4 historic quarters locked

Sign in to unlock the full Karyopharm Therapeutics Inc cash flow history.

Sign In Create Free Account

About Karyopharm Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-347906

Figures are derived from filed reports and may be restated. Historical data is subject to revision.